1. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy;Kohlhapp;Clin Cancer Res,2016
2. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties;Liu;Gene Ther,2003
3. IMLYGIC® (talimogene laherparepvec). Full Prescribing Information. Thousand Oaks, CA: Amgen Inc; 2023. Available at imlygic_pi.ashx (amgen.com). Accessed February 22, 2023.
4. IMLYGICTM. Summary of Product Characteristics. London, UK: European Medicines Agency; 2020. Available at https://www.ema.europa.eu/en/documents/product-information/imlygic-epar-product-information_en.pdf. Accessed February 22, 2023.
5. TECENTRIQ (Atezolizumab). Full Prescribing Information. South San Francisco, CA: Genentech Inc.; 2022. Available at tecentriq_prescribing.pdf (gene.com). Accessed February 22, 2023.